Because of this sort of loop, it is difficult to clarify with certainty the primary defects leading to the mitochondrial bioenergetic failure of frataxin deficient cells, and this makes it challenging to identify potential therapies or specific drug targets for FRDA. This evidence concerns the gene FXN and Friedreich ataxia.